Key Highlights

  • REZENOPY, a naloxone nasal spray, launched on August 12.
  • Second-quarter revenue rose about 510% sequentially.
  • The operating loss fell about 48% year on year to roughly $2.7 million.
  • A 1-for-25 reverse split was announced.

Scienture Holdings, Inc. (NASDAQ:SCNX), a pharmaceutical company focused on central nervous system and cardiovascular products, is in focus with a market capitalisation near $6.2 million. The company recently launched a product, announced a 1-for-25 reverse split and had trading halted around October 3 with news pending.

Latest Company Context

Scienture's pipeline includes SCN-102, an oral liquid losartan potassium in Phase 1, and SCN-104, a multi-dose DHE injection pen. On the commercial side, it announced the launch of REZENOPY, a naloxone nasal spray, on August 12, 2026. On September 22 it said distribution had expanded to addiction treatment centres, covering about 2,000 opioid treatment programme clinics, and around October 2 reported that Arbli oral suspension had been added to formularies at three U.S. pediatric academic medical centres.

For the second quarter of 2026, reported August 14, the company cited revenue up about 510% sequentially from the first quarter, gross margin of about 97.7% and an operating loss down about 48% year on year to roughly $2.7 million. Trailing revenue is listed at $821,315 and net loss at $37.95 million, though the page does not explain the net loss, which may include non-operating items.

Key Business Drivers

Scienture is moving from development toward commercial sales, so product uptake is the key driver. Very high growth rates reflect a small starting base. Formulary additions and distribution agreements can broaden access but do not guarantee prescriptions. Small-company financing needs, and the reverse split announced on September 30, are further considerations for share-price behaviour.

What Investors Should Watch

Investors may watch the explanation for the early-October trading halt, third-quarter results due in November, prescription trends for REZENOPY and Arbli, and any capital raising. The progress of SCN-102 and SCN-104 through development could also matter, as could Nasdaq compliance following the reverse split.

New Launches and a Reverse Split at a Very Small Scale

Scienture is launching products and expanding distribution while restructuring its share count. The net loss in the trailing figures is unexplained and may include non-operating items.